
Page#1
AMGEN INC.
CONSOLIDATED STATEMENTS OF INCOME
Years ended December 31, 2017, 2016 and 2015
(In millions, except per share data)
 
2017 2016 2015
Revenues: 
Product sales $ 21,795  $ 21,892  $ 20,944
Other revenues 1,054  1,099  718
Total revenues 22,849  22,991  21,662
 
Operating expenses: 
Cost of sales 4,069  4,162  4,227
Research and development 3,562  3,840  4,070
Selling, general and administrative 4,870  5,062  4,846
Other 375  133  49
Total operating expenses 12,876  13,197  13,192
 
Operating income 9,973  9,794  8,470
 
Interest expense, net 1,304  1,260  1,095
Interest and other income, net 928  629  603
 
Income before income taxes 9,597  9,163  7,978
 
Provision for income taxes 7,618  1,441  1,039
 
Net income $ 1,979  $ 7,722  $ 6,939
 
Earnings per share: 
Basic $ 2.71  $ 10.32  $ 9.15
Diluted $ 2.69  $ 10.24  $ 9.06
 
Shares used in the calculation of earnings per share: 
Basic 731  748  758
Diluted 735  754  766
See accompanying notes.
F-2
Page#2
AMGEN INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Years ended December 31, 2017, 2016 and 2015
(In millions)
 
2017 2016 2015
Net income $ 1,979  $ 7,722  $ 6,939
Other comprehensive (loss) income, net of reclassification adjustments and taxes:  
Foreign currency translation gains (losses) 81  (99)  (247)
Effective portion of cash flow hedges (288)  (15)  7
Net unrealized (losses) gains on available-for-sale securities (6)  122  (241)
Other 5  1  9
Other comprehensive (loss) income, net of tax (208)  9  (472)
Comprehensive income $ 1,771  $ 7,731  $ 6,467
See accompanying notes.
F-3
Page#3
AMGEN INC.
CONSOLIDATED BALANCE SHEETS
December 31, 2017 and 2016
(In millions, except per share data)
  
2017 2016
ASSETS
Current assets: 
Cash and cash equivalents $ 3,800  $ 3,241
Marketable securities 37,878  34,844
Trade receivables, net 3,237  3,165
Inventories 2,834  2,745
Other current assets 1,727  2,015
Total current assets 49,476  46,010
 
Property, plant and equipment, net 4,989  4,961
Intangible assets, net 8,609  10,279
Goodwill 14,761  14,751
Other assets 2,119  1,625
Total assets $ 79,954  $ 77,626
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities: 
Accounts payable $ 1,352  $ 917
Accrued liabilities 6,516  5,884
Short-term borrowings and current portion of long-term debt 1,152  4,403
Total current liabilities 9,020  11,204
 
Long-term debt 34,190  30,193
Long-term deferred tax liabilities 1,166  2,436
Long-term tax liabilities 9,099  2,419
Other noncurrent liabilities 1,238  1,499
 
Contingencies and commitments 
 
Stockholders’ equity: 
Common stock and additional paid-in capital; $0.0001 par value per share; 2,750.0 shares authorized;
outstanding—722.2 shares in 2017 and 738.2 shares in 2016 30,992  30,784
Accumulated deficit (5,072)  (438)
Accumulated other comprehensive loss (679)  (471)
Total stockholders’ equity 25,241  29,875
Total liabilities and stockholders’ equity $ 79,954  $ 77,626
See accompanying notes.
F-4
Page#4
AMGEN INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
Years ended December 31, 2017, 2016 and 2015
(In millions)
 
2017 2016 2015
Cash flows from operating activities: 
Net income $ 1,979  $ 7,722  $ 6,939
Depreciation and amortization 1,955  2,105  2,108
Stock-based compensation expense 329  311  322
Deferred income taxes (1,330)  183  (607)
Other items, net 334  32  (146)
Changes in operating assets and liabilities, net of acquisitions:  
Trade receivables, net (58)  (214)  (420)
Inventories 133  (80)  481
Other assets (24)  (128)  155
Accounts payable 424  (44)  (12)
Accrued income taxes, net 523  (301)  509
Long-term tax liability 6,681  445  409
Other liabilities 231  323  (7)
Net cash provided by operating activities 11,177  10,354  9,731
Cash flows from investing activities: 
Purchases of property, plant and equipment (664)  (738)  (594)
Cash paid for acquisitions, net of cash acquired (19)  —  (359)
Purchases of marketable securities (33,607)  (28,094)  (25,977)
Proceeds from sales of marketable securities 24,240  17,958  18,029
Proceeds from maturities of marketable securities 6,174  2,459  3,527
Proceeds from sales of property, plant and equipment 11  78  274
Other (159)  (321)  (447)
Net cash used in investing activities (4,024)  (8,658)  (5,547)
Cash flows from financing activities: 
Net proceeds from issuance of debt 4,476  7,318  3,465
Repayment of debt (4,405)  (3,725)  (2,400)
Repurchases of common stock (3,160)  (2,965)  (1,867)
Dividends paid (3,365)  (2,998)  (2,396)
Settlement of contingent consideration obligations —  —  (253)
Withholding taxes arising from shares withheld for share-based payments (191)  (260)  (401)
Other 51  31  81
Net cash used in financing activities (6,594)  (2,599)  (3,771)
Increase (decrease) in cash and cash equivalents 559  (903)  413
Cash and cash equivalents at beginning of year 3,241  4,144  3,731
Cash and cash equivalents at end of year $ 3,800  $ 3,241  $ 4,144
See accompanying notes.
F-6